WALTHAM, Mass.–(BUSINESS WIRE)–Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, today announced…

Click here to view the original article.